🏛️ Verified NIH Record • Updated 2025-12-19

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (NCT04647526)

A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the efficacy and safety of \[Lu-177\]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).

Who can join: Review the eligibility criteria below.

Location: Arizona Institute of Urology (AIU) - Tucson — Tucson, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (54 Sites)

Showing the first 25 of 54 sites.

  • Arizona Institute of Urology (AIU) - Tucson — Tucson, Arizona
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California
  • VA Greater Los Angeles Healthcare System — Los Angeles, California
  • University of California Los Angeles, Nuclear Medicine Clinic — Los Angeles, California
  • Hoag Memorial Hospital Presbyterian — Newport Beach, California
  • UC Irvine Chao Family Comprehensive Cancer Center — Orange, California
  • Stanford Cancer Institute — Palo Alto, California
  • University of Colorado Hospital — Aurora, Colorado
  • H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida
  • University of Iowa Hospitals and Clinics — Iowa City, Iowa
  • University of Kentucky Chandler Medical Center — Lexington, Kentucky
  • Tulane University Medical Center — New Orleans, Louisiana
  • University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
  • Chesapeake Urology Associates (CUA) P.A. — Towson, Maryland
  • University of Michigan Hospitals — Ann Arbor, Michigan
  • Karmanos Cancer Center — Detroit, Michigan
  • VA St. Louis Health Care System — St Louis, Missouri
  • Saint Louis University Hospital — St Louis, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Urology Cancer Center, PC — Omaha, Nebraska
  • Astera Cancer Care — East Brunswick, New Jersey
  • New Mexico Oncology Hematology Consultants Ltd., New Mexico Cancer Center — Albuquerque, New Mexico
  • New York Presbyterian Hospital/Weill Cornell Medical Center — New York, New York
  • Tri-State Urologic Services — Cincinnati, Ohio
  • Greater Dayton Cancer Center — Kettering, Ohio

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Castration-Resistant Prostate Cancer

Explore by condition: All Metastatic Castration-Resistant Prostate Cancer clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗